Advertisement

Topics

Reduced Retreatment Dose Feasible in Relapsed, Refractory Multiple Myeloma

21:34 EDT 18 Aug 2017 | Cancer Networks

Prolonged use of bortezomib after treatment with combined bortezomib plus dexamethasone did not result in any significant benefit for patients with relapsed/refractory multiple myeloma compared with bortezomib plus dexamethasone alone, but this less dose-intensive approach could be a feasible option for patients who cannot tolerate the standard regimen.

Original Article: Reduced Retreatment Dose Feasible in Relapsed, Refractory Multiple Myeloma

NEXT ARTICLE

More From BioPortfolio on "Reduced Retreatment Dose Feasible in Relapsed, Refractory Multiple Myeloma"

Advertisement
Quick Search
Advertisement
Advertisement